



COLORADO

Department of Health Care
Policy & Financing

DUR BOARD MEETING AGENDA

February 9, 2021

1:00 p.m. - 5:00 p.m. Open Session

Zoom Link will be posted at

<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

prior to the meeting

Health First Colorado, Colorado Medicaid
Drug Utilization Review Board

DUR Board Members	CO-DUR Team
Michael Noonan, DO (Chair)	Jeffrey Taylor, PharmD (HCPF)
Miroslav Anguelov, PharmD	Rachele Crane, PharmD (HCPF)
Todd Brubaker, DO	Julia Rawlings, PharmD (CO-DUR)
Liza Wilson Claus, PharmD	Robert L Page II, PharmD, MSPH (CO-DUR)
Allison Blackmer, PharmD	Heather Anderson, PhD (CO-DUR)
William Lai, PharmD	Garth Wright, MPH (CO-DUR)
Patricia Lanius, MHA, RPh	Gina Moore, PharmD, MBA (CO-DUR)
Alison Shmerling, MD, MPH	Vanessa Patterson, MPH (CO-DUR)
Scott VanEyck, MD	

1. Call to Order and Board Member Roll Call, and Introductions
2. Announcements
3. Vote for New Board Chair and Vice Chair
4. Approval of Minutes from the November 10, 2020 Meeting
5. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest
 - Agenda items must be approved in advance, including requests to present information. Please contact the DUR Pharmacist, Jeff Taylor, at jeffrey.taylor@state.co.us with questions.
 - Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours before the meeting.

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.

www.colorado.gov/hcpf



Open Session:

6. Updates on Business from Last Meeting

(Items included in this section are not scheduled for public testimony or board review as part of this agenda)

- Non-Steroidal Anti-Inflammatories (NSAIDs), Oral
- Non-Steroidal Anti-Inflammatories (NSAIDs), Non-Oral
- Antibiotics, Inhaled
- Hepatitis C Virus Treatments - Direct-Acting Antivirals (DAAs)
- Pulmonary Arterial Hypertension (PAH) Agents
 - Phosphodiesterase Inhibitors (PDEIs)
 - Endothelial Antagonists
 - Prostanoids
 - Guanylate Cyclase Stimulators
- Triptans and other Migraine Treatments, Oral & Non-Oral
- Antipsoriatics, Oral
- Antipsoriatics, Topical
- Antiemetics
- *H. Pylori* Treatments
- Methotrexate Products
- Targeted Immune Modulators (TIMs)
- Antihyperuricemics
- **Mass review drug classes*:**
 - Antiherpetic Agents, Oral and Topical
 - Fluoroquinolones, Oral
 - Hepatitis C Virus Treatments - Ribavirin Products
 - Newer Generation Antidepressants
 - Monoamine Oxidase Inhibitors (MAOIs)
 - Tricyclic Antidepressants (TCAs)
 - Pancreatic Enzymes
 - Proton Pump Inhibitors
 - Non-Biologic Ulcerative Colitis Agents, Oral & Rectal
 - Antiplatelet Agents
 - Epinephrine (self-administered) Products

Proposed ProDUR and Prior Authorization Criteria for Other Selected Products

- Evrildi (rizdipam) oral solution
- Engspynq (satralizumab-mwge) subcutaneous injection

**Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.*

7. New Business (open for public testimony and board review)

Proposed ProDUR and Prior Authorization Criteria for Pharmacy Benefit Preferred Drug List (PDL) Products

- Diabetes Management - Insulins
- Lipotropics

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.

www.colorado.gov/hcpf



- Cardiovascular Agents
 - Alpha-Blockers
 - Beta-Blockers
 - Calcium Channel Blockers & Combinations
- Leukotriene Modifiers
- Multiple Sclerosis Agents
- Anti-Parkinson’s Agents
 - Dopa Decarboxylase Inhibitors & Combinations
 - MAO-Bs
 - Dopamine Agonists
 - Other
- Antimigraine Agents - Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- Atypical Antipsychotics
- Sedative Hypnotics
 - Non-Benzodiazepine
 - Benzodiazepine
- Anxiolytics
- Hemorrhoidal and Related Anorectal Agents
- Ophthalmics, Anti-Inflammatory
- Ophthalmics, Glaucoma Agents
- Mass review drug classes*
 - Statins & Statin Combinations
 - Lithium Agents
 - Neurocognitive Disorder Agents
 - Topical Steroids
 - Low Potency
 - Medium Potency
 - High Potency
 - Very High Potency
 - Glucagon, Self-Administered
 - Growth Hormones
 - Bile Salts
 - Immune Globulins
 - Intranasal Rhinitis Agents
 - Ophthalmic Allergy Agents

**Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.*

Proposed Prior Authorization Criteria for Medical Benefit Physician Administered Drug Products

(Products included for review in this section are identified by HCPCS J Code billing codes. Information regarding specific product formulations included in a listed J Code is available by referencing Appendix X at <https://www.colorado.gov/hcpf/billing-manuals#appendices> .)

- Neuromuscular Agents
 - Botox J0585
 - Myobloc J0587
 - Dysport J0586
 - Xeomin J0588

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
www.colorado.gov/hcpf



- Bone Resorption Inhibitor Agents
 - Prolia, Xgeva J0897
- Monoclonal Antibody Agents
 - Xolair J2357
 - Nucala J2182
 - Fasenra J0517
 - Cinqair J2786
 - Remicade J1745
 - Soliris J1300
 - Entyvio J3380
- Multiple Sclerosis Agents
 - Ocrevus J2350
 - Tysabri J2323
- Immune Globulin Agents
 - Gammaked, Gamunex-C, Gamunex J1561
 - Octagam 5%, 10% J1568
 - Gammagard Liquid J1569
 - Privigen J1459
 - Asceniv, Gammaplex, Panzyga J1599
 - Bivigam J1556
 - Flebogamma DIF J1572
 - Gammagard S/D J1566
 - Gammaplex J1557

Proposed ProDUR and Prior Authorization Criteria for Other Selected Pharmacy Benefit Products

- Lampit (nifurtimox) oral tablets
- Bynfezia (octreotide acetate injection)
- Xywav (calcium, magnesium, potassium, sodium oxybates)
- Jynarque (tolvaptan)
- Uplinza (inebilizumab)
- Viltepsa (viltolarsen)
- Hemady (dexamethasone)

8. Unfinished Business and General Orders

- Retrospective DUR Updates
- Quarterly Module Summary
- Quarterly Drug Utilization Reports
- Provider Letters

9. Adjournment

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at jeffrey.taylor@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

The next meeting of the Colorado DUR Board is tentatively scheduled for **May 11, 2021 from 1:00 to 5:00 pm**

